<PAGE>
FORM 8-K
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
March 23, 1995
ROBERTS PHARMACEUTICAL CORPORATION
- - --------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
New Jersey 1-10432 22-2429994
- - ---------------- ------------ --------------
(State or other (Commission (IRS Employer
jurisdiction File Number) Identification
of incorporation) Number)
Meridian Center II
4 Industrial Way West
Eatontown, New Jersey 07724
- - --------------------------------------------------------------------------------
(Address of principal executive offices, including zip code)
Registrant's telephone number, including area code: 908-389-1182
Meridian Center II
4 Industrial Way West
Eatontown, New Jersey 07724
- - --------------------------------------------------------------------------------
(Former name or former address, if changed from last report)
<PAGE>
-2-
Item 5. Other Events
------------
A preliminary review of Roberts' sales activity for the first
two months of 1995 indicates that sales and profit for the First Quarter of 1995
will be below Fourth Quarter 1994 results as well as below the First Quarter
1995 average estimate of the financial community drug industry analysts who
follow the Company. Upon compilation of the First Quarter results, Roberts will
make additional financial data available.
In accordance with previously announced plans, Roberts is
increasing its prescription pharmaceutical sales force by approximately 70
professional sales representatives. Of this amount, 45 have already been
employed. By mid-April, Roberts expects that approximately 90% of the newly
employed professional sales representatives will have been trained and will
be actively promoting Roberts' products. The effects of the increase in sales
personnel on future sales performance cannot be quantified at this time.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ROBERTS PHARMACEUTICAL CORPORATION
----------------------------------
(Registrant)
Date: March 23, 1995 By: /s/ Anthony A. Rascio
----------------------------------
Anthony A. Rascio
Vice President
